TP53 and non-small cell lung carcinoma: Recent studies involving patients with non-small cell lung cancer (NSCLC) and a mouse model, in which tail vein injections of KrasG12D-transduced and p53-deficient lung epithelial cells were used, have highlighted the significant role of tissue-resident AMs in driving lung tumorigenesis [19].